Infors HT Schweiz

At OBaris, we are revolutionizing peptide drug delivery with OctoPatch®—a painless, patient-friendly platform designed to replace injections. Our innovative technology enables pharma partners to target various diseases, improving patient compliance and treatment outcomes.

XEMPERIA, a spin-off from the University of Fribourg, is pioneering a groundbreaking approach to blood testing that leverages the body's immune response to detect breast cancer at its earliest and most treatable stage.

Parithera is pioneering an AI-ready, clinical-grade liquid biopsy platform for single-cell analysis. Our platform is ideally positioned to study cancer treatment resistance.